Company ProfilePremium

Aarti Surfactants Ltd.

Company Profile Analysis

Tickers: AARTISURF.NS, 543210.BO

ESOMAR 23 Corporate BadgeISO Certifications Badge
Aarti Surfactants Ltd. - Company showcase

Year Founded & Workforce

2018

350 Employees

Aarti Surfactants Ltd. logo

Aarti Surfactants Ltd. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Aarti Surfactants Ltd. Overview

Aarti Surfactants Limited is a small-cap Indian maker of surfactants and specialty ingredients for home and personal care, carved out of Aarti Industries in 2019 and listed in 2020. From two plants at Pithampur and Silvassa, with roughly 113,000 tonnes a year of capacity, it supplies sulfonation products, betaines and milder specialty ingredients to consumer-goods majors including Hindustan Unilever, Procter & Gamble, Colgate-Palmolive, Dabur and ITC. It is one of the larger merchant suppliers in India, yet a fraction of the size of the domestic leader, Galaxy Surfactants. The business is volume-rich and margin-thin: cost-plus contracts pass palm-linked feedstock prices through to customers, so revenue swings with raw materials while operating margin has stayed in a 5 to 11 percent band. Two customers supplied about 71 percent of FY2026 revenue. The investment case rests on a multi-purpose plant under construction, a new R&D centre, and a slow shift toward higher-margin specialties.


What the company does. Aarti Surfactants manufactures ionic and non-ionic surfactants and specialty ingredients that go into detergents, dishwashing liquids, surface cleaners, shampoos, body washes, hand washes and skin-care formulations. The company describes itself on its website as one of the leading producers of ionic and non-ionic surfactants and specialty products, serving home and personal care, industrial applications, agro and oil industries in India and overseas. Its first annual report (FY2019) described a range of over 30 surfactants plus custom surfactants and formulated blends; the FY2025 annual report and the September 2026 AGM presentation cite 50+ products and 100+ customers.

Business model. This is a business-to-business process-chemistry operation. The company buys oleochemical and petrochemical feedstocks (chiefly lauryl alcohol, coconut fatty acid and alpha olefin), converts them through sulfonation, sulfation, amidation and related chemistries, and sells the output in bulk to consumer-goods formulators. Crisil states that core products are largely commoditised and sold under cost-plus arrangements with quarterly price resets. That structure makes the company closer to a tolling-style converter than a price-setting specialty house: absolute profit per tonne is relatively stable, while reported revenue and percentage margin move with feedstock prices.

Revenue model. Revenue is essentially 100 percent product sales. There is no disclosed service, subscription or licensing income. Other income is negligible in normal years; FY2025 included a one-time state industrial promotion incentive of INR 6.34 crore (Crisil).

Value chain position. The company sits midstream, between palm- and petro-based feedstock producers (largely import-linked) and branded FMCG formulators. It does not own upstream fatty alcohol capacity and does not sell consumer brands.

Customers and end-markets. Customers are multinational and domestic FMCG companies. CARE names Hindustan Unilever, Procter & Gamble Home Products, Colgate-Palmolive (India) and Dabur India; Crisil adds ITC. Supplier qualification takes 12 to 18 months according to Crisil, which protects incumbency. End-markets are home care (laundry, dishwash, surface care) and personal care (hair, bath, skin), with smaller sales to industrial, agrochemical and oilfield uses. Domestic sales were 82 percent of FY2026 revenue and exports 18 percent (AGM presentation summary).

Independent characterisation. The company is best understood as the second-tier Indian merchant surfactant supplier with a concentrated blue-chip customer book, a commodity-heavy mix, and a balance sheet that has been repaired since 2022. Its strategic question is whether new capacity and R&D can lift the specialty share enough to move operating margin sustainably above the mid-single digits.

Strategy

Stated themes. Management's published messaging (FY2025 annual report; September 2026 AGM presentation, as summarised in exchange-filing coverage) centres on five themes, paraphrased here: (1) research and innovation as the basis of the company's value proposition in specialty surfactants; (2) quality, innovation and customer-centricity to be a trusted supplier of high-performance surfactants; (3) digital and process automation to raise plant uptime and efficiency; (4) capacity utilisation and operating efficiency to defend margins against input-cost, freight and pricing pressure; and (5) expansion in higher-margin skin-care ingredients.

Initiatives announced in the last 24 months

Cost programmes. No quantified cost-reduction programme has been disclosed.

Medium-term financial targets. The company has not published numerical guidance in the sources reviewed. The only forward numbers in the public domain are rating-agency expectations: Crisil expects net cash accrual above INR 40 crore in FY2027 and INR 42 to 50 crore a year thereafter, interest cover of 5 to 7 times, gearing of 0.35 to 0.40 times over the medium term, and ROCE moving to double digits.

Reading the objects-clause change. The widened memorandum is an enabling step and not a business plan. Combined with the appointment of a pharmaceutics professor as independent director, a multi-purpose plant and a US entity named "Precision Ingredients", it points toward a deliberate move into higher-value ingredients adjacent to pharma and personal care. No capex, product or customer announcement supports that reading yet.

Products & Services

The company does not publish a priced catalogue, and launch years and specifications by product are not disclosed in the sources reviewed. The table sets out product families named in company, CARE and Crisil descriptions. Chemical examples in the "typical chemistry" column are standard industry examples for the family and should be confirmed against the company's product list before being attributed to it.

Sources: Business Standard/Capital Market company description (May 2026); CARE Ratings (December 2025); Crisil (September 2026); company website; FY2019 Annual Report.

Flagship offerings. By volume, the flagship lines are the sulfonation products sold to the two largest customers. By strategic emphasis, management points to skin-care ingredients as the high-margin growth area (AGM presentation summary). Named brand or trade names for individual products are not publicly disclosed in the sources reviewed.

Services. No standalone service lines are disclosed. Custom synthesis and formulation support are embedded in product sales.

Product Portfolio

Product familyWhat it isTypical chemistry (industry examples)Main useTarget customerPricing model

Sulfonation products (anionic surfactants)

Primary cleansing and foaming agents; the company's volume backbone, made at the Pithampur sulfonation unit

Sulfonated and sulfated compounds derived from lauryl alcohol and alpha olefin

Detergents, dishwash liquids, shampoos, body and hand washes

Large FMCG formulators

Cost-plus with quarterly resets (Crisil)

CAPB and amphoteric surfactants

Secondary surfactants that add mildness and foam stability

Cocamidopropyl betaine from coconut fatty acid

Shampoos, body washes, hand washes

FMCG personal care

—

Mild surfactants

Low-irritation cleansers for premium and baby care

—

Face wash, baby care, sulfate-free formulations

Personal care brands

—

Non-ionic surfactants

Emulsifiers and foam boosters

—

Home care, personal care, industrial uses

FMCG and industrial

—

Rheology modifiers

Thickeners and viscosity builders

—

Liquid cleansers

Personal care

—

Pearlising agents

Give opacity and pearl effect

—

Shampoos, body washes

Personal care

—

UV filters

Sun-protection actives

—

Sun care and skin care

Skin care brands

—

Syndet and soap bases

Bases for synthetic detergent bars and soaps

—

Bathing bars

Soap makers

—

Conditioning agents and quats

Cationic conditioning ingredients

—

Hair conditioners, fabric care

Personal and fabric care

—

Proteins and active ingredients

Functional actives

—

Hair and skin care

Personal care

—

Blends and custom surfactants

Formulated blends and made-to-order surfactants

Customer specific

Customer formulations

Key accounts

—

Industrial, agro and oilfield surfactants

Surfactants for non-HPC uses

—

Agrochemical formulation, oil industry, industrial cleaning

Industrial buyers

—

“—” = not publicly disclosed.

Financial Narrative

All figures consolidated, INR crore unless stated. Source: Screener.in (from filed results), with decimals from the Anand Rathi results table where available. Gross profit is not reported in the sources reviewed (Indian results show cost of materials rather than gross profit), so no gross profit row is given.

Income statement

Diluted EPS is not separately shown by the aggregator; the standalone diluted EPS reported in the AGM presentation was INR 17.71 for FY2025 and INR 14.96 for FY2026.

Revenue CAGR: 10.5 percent over FY2022 to FY2026 (four years, derived); 13 percent over FY2021 to FY2026 (five years, Screener).

Commentary. Three things stand out. First, revenue is a poor guide to earnings. FY2026 revenue was 49 percent above FY2022, yet EBIT was only about INR 9 crore higher. Second, the margin cycle follows feedstock. FY2024 benefited from falling input costs against lagged prices; FY2025 and FY2026 saw the reverse as fatty alcohol prices climbed sharply (Galaxy Surfactants reported average fatty alcohol prices rising from about USD 1,926 per tonne in Q2 FY2025 to about USD 2,800 in Q2 FY2026). CARE states plainly that the company had limited ability to pass on the increases in time. Third, fixed charges are heavy relative to EBITDA: depreciation plus interest consumed INR 30 crore of INR 47 crore of FY2026 EBITDA, which is why small margin moves produce large swings in net profit.

Balance sheet

Debt split (FY2025 Directors' Report, consolidated). Long-term borrowings, including the 0% preference shares, were INR 27.60 crore at 31 March 2025 against INR 47.93 crore a year earlier. Short-term borrowings were INR 81.13 crore against INR 49.29 crore.

Cash and net debt. Crisil reports an unencumbered liquid surplus of INR 13 crore at 31 March 2026, implying net debt of roughly INR 90 crore.

Goodwill and intangibles. No goodwill is evident (the company has made no acquisitions). Intangible assets are not separately shown in the sources reviewed.

Working capital. Screener shows working capital days of 16, 20, 40, 36 and 22 for FY2022 to FY2026.

Commentary. Leverage has roughly halved in relative terms. Debt to equity fell from 1.19 times in FY2022 to 0.43 times in FY2026, helped by the 2023 rights issue (equity rose by about INR 48 crore more than retained profit across FY2023 and FY2024, consistent with staged receipt of issue proceeds) and by strong FY2024 cash flow. CWIP rising to INR 45 crore in FY2026 marks the start of the new capex cycle. Payables growth (other liabilities up INR 34 crore in FY2026) funded much of the higher-priced inventory and receivables.

Cash flow

Dividends paid: none in FY2022 to FY2025; the INR 1 per share dividend for FY2025 (about INR 0.85 crore) was paid in FY2026, and the same amount for FY2026 was approved on 29 September 2026. No buyback has been announced.

Commentary. FY2026 operating cash flow of INR 77 crore was 1.7 times operating profit, driven by a release of inventory days (92 to 60) and higher payables. That working capital benefit is unlikely to repeat at the same scale. FY2025 was the mirror image: inventory build at rising prices cut operating cash flow to INR 11 crore.

Ratios

Net debt to EBITDA for FY2026 is about 1.9 times using Crisil's INR 13 crore liquid surplus.

Rating-agency versions of the same ratios. Crisil: adjusted gearing 0.43 times (FY2026) and 0.47 times (FY2025); interest coverage 3.85 times and 3.95 times; ROCE 8.2 percent in FY2026. CARE: total debt to PBILDT 1.60 times (FY2024), 3.18 times (FY2025), 2.80 times (H1 FY2026); interest coverage 4.41, 3.00 and 3.46 times. The AGM presentation (standalone) shows ROCE falling from 11.54 percent to 9.72 percent and ROE from 6.61 percent to 5.27 percent. The differences reflect each party's definitions.

Commentary. Returns are below any reasonable cost of capital in four of five years. ROE has averaged about 7 percent. The single year above 10 percent (FY2024) needed a favourable feedstock tailwind. The improvement the company can point to is in balance-sheet risk, not in returns.

Recent quarters (consolidated, INR crore)

Source: Screener. Q1 FY2027 (quarter ended 30 June 2026) was the strongest quarter since Q4 FY2025; Crisil notes the margin improvement included inventory gains that it expects to be temporary.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Revenue by Segment and Segment Margins & Growth (%)

MetricFY2024FY2025FY2026

Segment revenue: HPC surfactants and specialty ingredients (INR Cr)

589.86659.09859.13

YoY revenue growth (%)

-1.911.730.3

Share of total revenue (%)

100100100

Operating profit before other income, depreciation and interest (INR Cr)

624247

Operating margin (%)

10.56.45.5

Pre-tax profit (INR Cr)

32.1920.7017.22

Pre-tax margin (%)

5.53.12.0

Income Statement and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Revenue from operations (INR Cr)

575.52601.29589.86659.09859.13

Operating profit before other income (INR Cr)

3248624247

Other income (INR Cr)

00080

EBITDA including other income (INR Cr)

3248625047

Depreciation (INR Cr)

1215161718

Operating income, EBIT (INR Cr, derived)

2033463329

Interest (INR Cr)

1115141212

Pre-tax income (INR Cr)

9.3217.8032.1920.7017.22

Net income (INR Cr)

5.4912.7021.3314.5512.34

EPS, basic (INR)

6.4614.9425.2217.1914.58

Dividend per share (INR)

00011

Margin / growth

Margin / growthFY2022FY2023FY2024FY2025FY2026

Revenue growth (%)

23.64.5-1.911.730.3

Operating margin before other income (%)

5.68.010.56.45.5

EBITDA margin including other income (%)

5.68.010.67.55.5

EBIT margin (%)

3.55.57.85.03.4

Net margin (%)

1.02.13.62.21.4

Effective tax rate (%)

4129343028

Balance Sheet

Metric (INR Cr)FY2022FY2023FY2024FY2025FY2026

Total assets

402404422477517

Net fixed assets (incl. intangibles)

173207208204200

Capital work in progress

52881545

Other assets (mainly current)

178188206259272

Total debt

16214999110104

Shareholders' equity (capital plus reserves)

136168218232244

Other liabilities (mainly payables)

10586105134168

Cash Flow

Metric (INR Cr)FY2022FY2023FY2024FY2025FY2026

Operating cash flow

2325521177

Investing cash flow

-23-11-16-16-46

Financing cash flow

-6-8-370-19

Net cash flow

-56-1-512

Free cash flow (Screener definition)

11436-932

Capex (derived: operating cash flow minus free cash flow)

2211162045

Buybacks

00000

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2022FY2023FY2024FY2025FY2026

ROCE (%) (Screener)

7111589

ROE (%) (derived, on average equity)

4.18.411.16.55.2

ROA (%) (derived, on average assets)

1.43.25.23.22.5

Debt / equity (x) (derived)

1.190.890.450.470.43

Gross debt / EBITDA (x) (derived)

5.03.11.62.22.2

Interest coverage, EBITDA / interest (x) (derived)

2.93.24.44.13.9

Asset turnover (x) (derived, on average assets)

1.461.491.431.471.73

Debtor days (Screener)

3540434244

Inventory days (Screener)

6060819260

Payable days (Screener)

5644556362

Cash conversion cycle, days (Screener)

3855697143

Margin Analysis (%) and Per-Share Data

MetricQ1 FY2026Q2 FY2026Q3 FY2026Q4 FY2026Q1 FY2027

Revenue

215.90179.17207.79256.28272.87

Operating profit

11.639.3412.6913.2120.29

Operating margin (%)

5.395.216.115.157.44

Pre-tax profit

4.042.195.105.8812.19

Net profit

2.941.563.664.199.00

EPS (INR)

3.481.844.324.9510.62

Revenue by Region (%) and Revenue by Region

RegionFY2025FY2026

Domestic (India) share of revenue (%)

8282

Export share of revenue (%)

1818

Domestic revenue (INR Cr, derived from share)

540704

Export revenue (INR Cr, derived from share)

119155

Capital Markets

ItemValue

Share price

INR 494

Market capitalisation

INR 418 crore

52-week high / low

INR 680 / INR 316

Trailing P/E

22.7 times (trailing EPS INR 21.73)

Price to book

1.71 times (book value INR 289 per share)

Dividend yield

0.20 percent

EV/EBITDA (derived)

About 9 times (EV of roughly INR 510 crore using March 2026 net debt; trailing operating profit INR 56 crore)

EV/Sales (derived)

About 0.56 times (trailing sales INR 916 crore)

1 Year by Period

Period1 year3 years5 years

Stock price CAGR (%)

6-8-19

Per-Share Data and Returns & Leverage Ratios (%)

MetricFY2022FY2023FY2024FY2025FY2026

Dividend per share (INR)

00011

Payout ratio (%)

00067

Credit Ratings

AgencyInstrumentRatingDateAction

Crisil Ratings

Bank facilities, INR 200 crore

Crisil A-/Stable

2 September 2026

Assigned

CARE Ratings

Long-term bank facilities, INR 208.87 crore

CARE BBB+; Stable

19 December 2025

Downgraded from A-; Stable

CARE Ratings

Preference shares, INR 18.50 crore

CARE BBB; Stable

19 December 2025

Downgraded from BBB+; Stable (instrument since redeemed)

CARE Ratings

Bank facilities

CARE A-; Stable

28 June 2024; 27 June 2025

Upgraded, then reaffirmed

CARE Ratings

Bank facilities

CARE BBB+; Stable

24 August 2022; 7 August 2023

Assigned, reaffirmed

Debt Facilities

FacilityLenderAmount (INR Cr)Maturity

Fund-based working capital

HSBC

55

Revolving

Fund-based working capital

SVC Co-operative Bank

70

Revolving

Term loan (capex)

HSBC

60

31 May 2031

Term loan

HSBC

4.5

30 September 2026

Proposed long-term facility

Unallocated

10.5—

Analyst Conclusions

Management guidance. No numerical guidance has been published in the sources reviewed. Management's qualitative message is efficiency, utilisation and a move toward skin-care and specialty ingredients.

External expectations. Crisil expects FY2027 revenue growth to be driven largely by realisations with steady volumes; operating margin to improve gradually as the multi-purpose plant ramps; net cash accrual above INR 40 crore in FY2027; and capex of INR 50 to 60 crore in FY2027. There is no sell-side consensus.

Bull case

  1. Earnings are near a cyclical low and already turning. Q1 FY2027 net profit of INR 9.0 crore is close to three-quarters of all of FY2026, and trailing EPS has recovered to INR 21.73.

  2. New capacity changes the mix. A multi-purpose plant plus an R&D centre gives the company, for the first time, the means to sell smaller-volume specialties; Crisil's upgrade trigger of 12 to 14 percent margin shows what a successful shift would look like.

  3. The balance sheet can carry the plan. Gearing of 0.43 times, an A- rating, the preference shares redeemed and unused bank lines mean the expansion does not need equity.

Bear case

  1. The margin recovery may be inventory, not structure. Crisil says first-quarter gains are temporary, and cost-plus contracts tie profit to feedstock direction.

  2. Two customers are the business. At about 71 percent of revenue, a sourcing change at either would outweigh any benefit from new products; the same customers cap pricing.

  3. Returns do not cover the cost of capital. ROE has averaged about 7 percent over five years, and another INR 85 to 100 crore is being invested, partly with debt, while project cost estimates already differ between rating agencies. Legal and governance signals (customs penalty naming the CEO, an independent director leaving within a year) add to the discount.

Catalysts and monitorables for the next 12 months

Analyst verdict. Aarti Surfactants is a sound operating business that has not yet shown it can earn an adequate return. Its franchise is real: it supplies India's largest consumer-goods companies from two established plants, its approvals take over a year to replicate, and its lenders now view it as an A-minus credit. Since listing it has cut gearing by more than half and redeemed its legacy preference shares without fresh equity beyond the 2023 rights issue.

The record on profitability is weaker. Revenue has grown about 13 percent a year since FY2021, yet FY2026 net profit of INR 12.3 crore was barely more than half the FY2021 figure. Cost-plus contracts mean growth in sales is mostly growth in feedstock prices, and margin depends on which way those prices are moving. One good year in five does not justify the capital employed, and the share price, down roughly 19 percent a year over five years, reflects that.

What could change the picture is now visible and dated. A multi-purpose plant is due by the end of 2026, an R&D centre is running, a US subsidiary exists, and the company has widened its charter and added scientific expertise to its board. If these lift the specialty share, margins of 8 to 10 percent are plausible and the stock, at about half of sales, would look inexpensive. If they do not, the company will have added debt and depreciation to a commodity base that two customers control.

On balance the evidence supports a cautious, watchful stance. The first-quarter rebound is encouraging but partly transient, and the customs order and board turnover deserve attention. The decisive data points are the next two quarterly margins and the commissioning of the new plant. Until those are in hand, the improvement is in the balance sheet and has yet to reach the income statement.


APPENDIX — DATA GAPS AND VERIFICATION FLAGS

ItemStatus
FY2026 Annual Report and AGM presentation full textdetails taken from filing summaries
Gross profit, five years—
Cash balances FY2022 to FY2025—
FY2026 short-term and long-term debt split—
Executive and director remuneration—
Top ten shareholders by name—
R&D expenditure, five years; patent count—
Rights issue price and size (2023)—
Exact listing date in July 2020; date of registered office shift to Madhya Pradesh—
Export share for FY2024; country-level revenue—
Capacity by plant; utilisation—
Market size figures for surfactantsomitted
Peer financials other than Galaxy Surfactants—
Project cost of ongoing capexSources conflict: CARE about INR 85 crore; Crisil INR 100 crore
FY2025 EBITDASources conflict: INR 45.4 crore, INR 49.6 to 49.8 crore, and CARE PBILDT INR 34.7 crore, by definition
One-year share price returnSources conflict: +6 percent (Screener) versus −7.37 percent (ScanX)
Current statutory auditor and registrarTo be confirmed in FY2026 Annual Report

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleTenure and backgroundSource

Mulesh Manilal Savla

Chairman; Independent Director

On the board since the company's formation period; chaired the 8th AGM

Company website; FY2019 Annual Report

Nikhil Parimal Desai

CEO and Managing Director; promoter group

Leads the company since demerger; over 20 years in IT, project management and business strategy in pharma and chemicals; reappointed for five years from 20 August 2027 to 19 August 2032

ScanX; Crisil

Santosh Madhaorao Kakade

Whole-time Director (Executive Director)

Over three decades in plant operations and process development; reappointed for five years from 20 August 2027; liable to retire by rotation

ScanX

Chandrakant Vallabhaji Gogri

Non-Executive Director; promoter

Founder and Chairman Emeritus of Aarti Industries

CARE; Crisil

Parimal Hasmukhlal Desai

Non-Executive Director; promoter group

Co-founder of Aarti Industries and father of the Managing Director; on the board from 1 October 2025

Crisil; TheCompanyCheck

Dattatray Sidram Galpalli

Non-Executive Director

Reappointed on retirement by rotation at the 8th AGM

ScanX

Misha Bharat Gala

Independent Director

Woman independent director

Company website

Prof. Vandana B. Patravale

Independent Director

Appointed 22 August 2026 for five years to 21 August 2031; Ph.D. in Pharmaceutics; Senior Professor at the Institute of Chemical Technology, Mumbai

ScanX

Executive Leadership Team

NameTitleNotes

Nikhil P. Desai

CEO and Managing Director

See above

Santosh M. Kakade

Executive Director

See above

Nitesh Medh

Chief Financial Officer

TheCompanyCheck

Priyanka Chaurasia

Company Secretary

TheCompanyCheck

Kanika Rathore

President, Business and Operations

Promoted from Vice President on 22 August 2026 (ScanX)

Shareholding Trend

Holder categoryMar 2024Mar 2025Mar 2026Jun 2026

Promoters (%)

49.8149.9249.8849.84

Foreign institutional investors (%)

0.090.140.140.08

Domestic institutional investors (%)

0.000.800.000.00

Government (%)

0.010.010.010.01

Public (%)

50.1049.1349.9850.07

Number of shareholders

43,09138,54835,66935,149

Competitive Landscape

Key Competitors

CompetitorHome marketOverlap with the companyRelative position

Galaxy Surfactants

India

Direct: performance surfactants and specialty care for the same FMCG buyers

Domestic leader; about six times the company's revenue; plants in India, Egypt and the US; 215+ grades

Godrej Industries (Chemicals)

India

Fatty alcohols and surfactants

Backward integrated into oleochemicals

BASF

Germany

Full personal and home care ingredient range

Global leader; technology and breadth

Stepan Company

United States

Anionic surfactants, sulfonation

Global sulfonation specialist

Clariant

Switzerland

Mild surfactants and specialties

Specialty focus

Croda International

United Kingdom

Premium personal care actives

High-margin specialist

Evonik Industries

Germany

Betaines and specialties

Strong in amphoterics

Solvay / Syensqo

Belgium

Surfactants and polymers for HPC

Global formulator partner

Dow

United States

Non-ionic surfactants, rheology

Scale petrochemical integration

Kao

Japan

Fatty alcohol derivatives

Integrated oleochemical player

Fine Organic, Rossari Biotech

India

Adjacent specialty additives and HPC ingredients

Higher-margin specialty niches

Peer Comparison FY2026

MetricAarti Surfactants (FY2026)Galaxy Surfactants (FY2026)

Revenue

INR 859 crore

INR 5,270 crore total income

Revenue growth

+30 percent

About +25 percent (largely pricing)

EBITDA

INR 47 crore

INR 497 crore

EBITDA margin

5.5 percent

9.4 percent

Net profit

INR 12.3 crore

INR 267 crore

Market capitalisation

About INR 418 crore

About INR 6,500 to 8,000 crore during 2026

Company Snapshot

$99.2M

Revenue

350

Employees

2018

Founded

Mumbai, India

Headquarters

SWOT Analysis

Strengths

  • Blue-chip customer base: Hindustan Unilever, P&G, Colgate-Palmolive, Dabur and ITC are named customers (CARE; Crisil).
  • Entry barriers: supplier qualification cycles of 12 to 18 months (Crisil).
  • Scale in its niche: about 113,000 tonnes per annum across two plants (CARE; Crisil).
  • Repaired balance sheet: debt to equity down from 1.19 times (FY2022) to 0.43 times (FY2026); Crisil A-/Stable.
  • Cash generation in FY2026: operating cash flow of INR 77 crore against operating profit of INR 47 crore (Screener).
  • Liquidity headroom: INR 125 crore working capital limit used at 59 percent on average, a cushion of about INR 43 crore (Crisil).
  • Promoter pedigree: Aarti Group founders on the board; promoter holding steady near 49.8 percent with no reported pledge in sources reviewed.

Weaknesses

  • Thin margins: operating margin of 5.5 percent in FY2026 and net margin of 1.4 percent (Screener).
  • Customer concentration: top two customers about 71 percent of FY2026 revenue; top five about 92 percent of FY2025 revenue (Crisil; CARE).
  • Low returns: ROE of 5.2 percent and ROCE of about 8 to 9 percent in FY2026 (Screener; Crisil).
  • No feedstock integration and heavy import linkage for fatty alcohols (Crisil).
  • Limited pricing power: CARE cites limited ability to pass on raw material increases in FY2025 and H1 FY2026.
  • Negligible institutional ownership (0.08 percent) and sparse investor communication: two earnings calls on record (Screener).
  • Earnings volatility: quarterly net profit ranged from INR 0.80 crore to INR 9.72 crore within FY2025 alone (Screener).

Opportunities

  • Multi-purpose plant and capacity expansion of INR 85 to 100 crore, due to ramp from FY2027 (CARE; Crisil).
  • Specialty and skin-care mix shift supported by the Navi Mumbai R&D centre (FY2025 Annual Report; AGM presentation).
  • Europe via REACH registration (CARE).
  • United States via the new subsidiary, Precision Ingredients Inc (August 2026).
  • Wider objects clause permitting pharma, agro and fine chemical ingredients (AGM, 29 September 2026).
  • Regional and direct-to-consumer brands: Galaxy reports strong traction with non-tier-one and D2C customers in India, a segment that would diversify the company's book.
  • Lower interest burden: Crisil projects interest cover rising to 5 to 7 times as debt amortises.

Threats

  • Loss or downsizing of a top-two customer, flagged by Crisil as a downgrade trigger.
  • Feedstock spikes: both key inputs follow palm oil, giving no natural hedge (Crisil).
  • Project risk: delay or cost overrun on the MPP is a stated downgrade trigger (Crisil); CARE and Crisil already cite different project costs (INR 85 crore versus INR 100 crore).
  • Trade policy: US tariffs hit H1 FY2026 exports (CARE).
  • Competition from a much larger domestic rival and multinationals (CARE's competitor list).
  • Regulatory and legal: customs penalty of INR 1.54 crore with a personal penalty on the CEO (September 2026); environmental compensation order (June 2026).
  • Captive capacity and reformulation by FMCG customers during price spikes (Galaxy cited "tactical reformulation" in FY2026).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
–Q4 revenue INR 202 crore, net profit INR 9.72 crore; FY2025 revenue INR 659 crore, net profit INR 14.55 croreStrong exit quarter after a weak nine months
27 June 2025CARE reaffirms A-; StableExpectation of FY2026 improvement, later missed
August 2025Q1 FY2026: revenue INR 215.90 crore, net profit INR 2.94 croreRevenue up about 50 percent year on year on price; margin 5.4 percent
30 August 2025FY2025 Annual Report filed; dividend of INR 1 per share recommendedFirst dividend since FY2021
September 2025Investor presentation and earnings callOne of only two calls on record (the other in August 2024)
23 September 20257th AGMRoutine
1 October 2025Parimal H. Desai and Nisha B. Shah join the boardPromoter and independent additions
November 2025Q2 FY2026: revenue INR 179.17 crore, net profit INR 1.56 croreWeakest quarter of the year; GST-rate disruption and US tariffs cited by CARE
19 December 2025CARE downgrades to BBB+; Stable (bank loans) and BBB; Stable (preference shares)Margin below CARE's 7 percent threshold for a sustained period
February 2026Q3 FY2026: revenue INR 207.79 crore, net profit INR 3.66 crore, up 357.5 percent from a low baseMargin recovers to 6.1 percent
24 March 2026Share price about INR 351; later 52-week low of INR 316Trough valuation near 1.2 times book
9 to 10 May 2026Board approves FY2026 results; Q4 revenue INR 256.28 crore, net profit INR 4.19 crore (−56.9 percent); final dividend INR 1Full-year profit down 15 percent despite 30 percent revenue growth
Mid-May 2026Shares fall about 11 percent after results; market cap about INR 348 croreMarket reaction to margin miss
15 June 2026Environmental compensation order of INR 17.4 lakh from the DNH and DD Pollution Control CommitteeSmall in money; first disclosed environmental penalty
3 July 2026Board meeting on preference share redemption; record date fixedClears a legacy instrument
1 August 2026Board approves Q1 FY2027 results: revenue INR 272.87 crore, net profit INR 9.00 crore (+197 percent standalone)Best quarter in over a year; includes inventory gains
13 August 2026Shares rise about 7 percent to INR 612Reaction to results and sector read-across from Galaxy's record quarter
19 August 2026Preference shares fall due and are redeemed (about INR 23 crore)Removes refinancing overhang flagged by CARE
22 August 2026Board reappoints CEO and Executive Director from August 2027; appoints Prof. Patravale; promotes Kanika Rathore; proposes objects-clause changeLeadership continuity and strategic optionality
About 31 August 2026US subsidiary Precision Ingredients Inc incorporatedFirst overseas entity
2 September 2026Crisil assigns A-/Stable to INR 200 crore facilitiesRestores an A-category rating from a second agency
4 September 2026FY2026 Annual Report, AGM notice and dividend record date filedDisclosure
7 September 2026Newspaper notice on dispatch of annual reportRoutine
11 to 12 September 2026Independent director Nisha B. Shah resigns after about eleven monthsBoard churn; reason given as time commitments
About 24 to 25 September 2026Customs order: INR 1.54 crore penalty, confiscation of 171.444 tonnes of goods valued at INR 2.30 crore, personal penalty on CEO; appeal to CESTAT intendedLargest legal item on record
25 September 2026Trading window closure for Q2 FY2027Routine
29 September 20268th AGM; investor presentation; all ten resolutions passedObjects clause broadened; borrowing limits raised
1 October 2026Scrutiniser's report and Regulation 30 disclosure on director appointmentsRoutine

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

5 charts
Income Statement: Revenue & Gross Profit: Revenue from operations rose from INR 5,755.2 Mn in FY2022 to INR 8,591.3 Mn in FY2026.
Aarti Surfactants Ltd. — Income Statement: Revenue & Gross Profit
Series (INR Mn)FY2022FY2023FY2024FY2025FY2026
Revenue from operations5,755.26,012.95,898.66,590.98,591.3

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.